1. Introduction

Artificial Tissue Procurement Law concerns the legal rules governing the acquisition, manufacture, sourcing, testing, storage, transfer and clinical use of tissues that are engineered, biofabricated, or produced using biological and synthetic materials.

The term is not generally the name of a single, independently codified legal doctrine. Instead, it describes an emerging area at the intersection of biotechnology law, medical-device regulation, human-tissue law, intellectual property, bioethics, product liability and constitutional rights.

Artificial tissue procurement may involve:

Engineered human tissues: laboratory-grown skin, cartilage, bone, vascular tissue or organ-like constructs.

Cell-derived tissue products: tissues manufactured from human cells, stem cells or other biological starting materials.

Hybrid tissues: constructs combining living cells with synthetic scaffolds, polymers, hydrogels or other biomaterials.

Non-living tissue substitutes: synthetic materials intended to replace or support damaged biological tissue.

Donor-derived materials: human cells or tissue used as inputs for tissue engineering, including materials obtained from tissue banks.

The legal classification depends on what the material contains, how it is produced, its intended medical use and the jurisdiction concerned. A synthetic scaffold, a living cell-based construct and a donated human skin graft may be subject to different legal requirements.

Important distinction: In India, the Transplantation of Human Organs and Tissues Act, 1994 (THOTA) regulates the removal, storage and transplantation of human organs and tissues for therapeutic purposes and prohibits commercial dealings in them. The Ministry of Health and Family Welfare has expressly clarified that artificial organs are not regulated under that Act. Whether a particular engineered tissue falls within THOTA requires a separate analysis of its biological composition and legal classification.

India Code

+1

2. Meaning and scope of tissue procurement

Procurement is broader than purchasing. It includes the complete process through which the materials required to manufacture or transplant tissue are obtained and made available for clinical use.

Stage 1 — Legal sourcing and consent

Verify donor authorization, lawful collection, provenance, restrictions on use and any applicable consent for research or commercial development.

Stage 2 — Manufacture and processing

Establish traceability of cells and materials, validated manufacturing procedures, contamination controls and quality standards.

Stage 3 — Testing and regulatory authorization

Assess safety, identity, purity, potency, biological compatibility and the evidence required for the product's intended use.

Stage 4 — Distribution and clinical use

Maintain records, storage and transport conditions, professional qualifications, informed consent and adverse-event reporting.

A defect at any stage can create legal consequences. For example, a tissue product may be manufactured correctly but still be unlawful if the original cells were obtained without legally sufficient consent or if the product was supplied without required regulatory authorization.

3. Legal framework in India

A. Transplantation of Human Organs and Tissues Act, 1994

The principal statute for procuring human tissues for transplantation is the Transplantation of Human Organs and Tissues Act, 1994. Its purpose is to regulate tissue removal and transplantation and prevent exploitation and unlawful commercial dealings.

India Code

+1

The most relevant provisions include:

The precise application of each provision depends on the type of tissue, whether the donor is living or deceased, the purpose of removal and the statutory definitions. Section 19's wording specifically addresses commercial dealings in human organs; it should not automatically be treated as covering every sale of a synthetic or laboratory-manufactured tissue product.

IndiaCode

+2

B. Transplantation of Human Organs and Tissues Rules, 2014

The 2014 Rules establish operational requirements for human tissue procurement and transplantation. These include consent, appropriate personnel, donor screening, recordkeeping, tissue handling and traceability.

The tissue-bank requirements include:

Procurement by registered healthcare professionals or appropriately trained technicians.

Consent for procurement.

Records linking each tissue to its donor and documenting the personnel involved.

Screening and appropriate laboratory testing.

Standard operating procedures for retrieval, processing, sterilization, packaging, labelling, storage, distribution and transport.

Procedures for reporting serious adverse reactions.

Controls on access to donor records and protection of confidentiality.

These requirements are especially important where human tissue is obtained as a starting material for further processing. The rules do not, however, mean that every wholly synthetic tissue substitute is automatically regulated as donated human tissue.

IndiaCode

+2

C. Regulation of engineered tissue products

Where an engineered tissue product is not covered by THOTA, other Indian laws may be relevant, depending on the product's composition and intended use. These can include:

The Drugs and Cosmetics Act, 1940, and applicable rules, where the product falls within the relevant drug or medical-product framework.

The New Drugs and Clinical Trials Rules, 2019, where applicable to a new drug or regulated clinical investigation.

The Medical Devices Rules, 2017, where the product qualifies as a medical device.

The Bio-Medical Waste Management Rules, 2016, for applicable biomedical waste handling.

The Consumer Protection Act, 2019, where defective products or deficient services fall within its scope.

The Patents Act, 1970, for qualifying inventions, subject to statutory exclusions and other patentability requirements.

Privacy and data-protection legislation where identifiable donor, genomic or health information is processed.

These laws are not interchangeable. For example, authorization to conduct research does not necessarily establish authorization to market a product, and patent protection does not establish clinical safety.

4. Core legal principles governing procurement

4.1 Informed consent and donor autonomy

Consent is fundamental when procurement involves human tissue. Depending on the source and intended use, consent may need to cover removal, storage, processing, transplantation, research, future use and sharing with third parties.

A consent form for therapeutic donation should not automatically be interpreted as permission for unlimited commercial research. Tissue banks and manufacturers should identify the scope of authorization and determine whether additional consent or other legal authority is required for subsequent uses.

For living donors, informed consent must be meaningful and voluntary. Relevant questions include whether the donor understood the risks, whether there was coercion, and whether the donor had the capacity to make the decision.

4.2 Prohibition of exploitation

Human tissue procurement creates risks of coercion, trafficking, misleading promises and exploitation of economically vulnerable donors.

Under the Indian framework, lawful donation must be distinguished from prohibited commercial dealings in the human materials covered by the Act. Payments for legitimate removal, transportation or preservation expenses may be legally distinguishable from payments for the supply of prohibited human materials; the actual arrangement and applicable statutory provisions must be examined.

The position is different for a manufactured product. A company charging for laboratory processing, quality assurance or a legally marketable engineered tissue is not necessarily selling a human organ or tissue in the prohibited statutory sense. Classification and the actual transaction are decisive.

Ministry of Health and Family Welfare

+1

4.3 Quality, safety and traceability

A lawful procurement process should allow investigators and regulators to establish:

The source of the biological material.

The legal basis for obtaining it.

The identity and quality of the incoming material.

The manufacturing and processing history.

The testing and release decision.

The destination of the product and any subsequent adverse events.

For living engineered tissues, quality control may also require assessment of cell viability, microbial contamination, genetic stability, immunological compatibility and functional performance, depending on the product.

Failure to maintain reliable records may create regulatory problems and make it difficult to identify affected patients during a safety recall.

4.4 Fair access and allocation

Where donated tissues are scarce, procurement and allocation should follow transparent and medically defensible criteria. Relevant factors can include clinical urgency, compatibility, suitability and the governing allocation protocol.

A private purchaser should not automatically receive priority merely because they can pay more. Equally, a commercial manufacturer may be entitled to charge lawful manufacturing and supply costs for an authorized product, subject to the applicable regulatory and contractual framework.

4.5 Intellectual property and ownership

Tissue procurement raises difficult questions about who may control cells, cell lines, manufacturing methods and the resulting product.

The legal analysis should distinguish among:

A donor's rights concerning consent and authorized use.

A tissue bank's custody and handling responsibilities.

A manufacturer's rights in a patented process or qualifying invention.

Contractual rights in research results and confidential manufacturing information.

A patient's rights concerning treatment, information and privacy.

A patent over a technical process does not automatically confer ownership of a donor's body or eliminate consent obligations. Similarly, lawful possession of a tissue sample does not necessarily grant unrestricted permission to exploit it commercially.

5. Important case laws and judicial principles

The following decisions provide relevant legal principles for tissue procurement, consent, transplantation, commercial exploitation and product regulation. Some concern human organ transplantation rather than engineered tissues; they are therefore analogous authorities, not direct rulings on every artificial tissue product.

Case 1: Amar Singh Bhatia v. Sir Ganga Ram Hospital (Delhi High Court, 2024)

Subject: Regulation of transplantation and prevention of commercial exploitation.

The Court discussed the purpose of the transplantation legislation and the need to protect vulnerable donors from financial exploitation. It emphasized that transplantation is regulated, not categorically prohibited, and that authorities must assess applications in accordance with the statute rather than treating every non-relative donation as inherently unlawful.

Indian Kanoon

+1

Relevance to artificial tissue procurement: This reasoning is useful when distinguishing a legitimate, regulated biological-material supply chain from an arrangement involving prohibited payments or exploitation. However, the case does not independently determine whether the commercial manufacture of engineered tissue falls within THOTA.

Case 2: Kuldeep Singh v. State of Tamil Nadu (Supreme Court of India, 2005)

Subject: Jurisdiction and safeguards in non-relative donations.

The Supreme Court considered which state's Authorization Committee had jurisdiction to approve a proposed transplant involving a donor and recipient who were not near relatives. It stressed the need for scrutiny aimed at preventing commercial dealings in human organs.

NearLaw

+1

Legal principle: The statutory approval process must be applied by the competent authority, with attention to the actual relationship and circumstances of the proposed donation.

Relevance: In human-tissue procurement, the identity and authority of the institution approving collection and use matter. The decision is not, however, a direct ruling about synthetic scaffolds or laboratory-grown tissues.

Case 3: Parveen Begum v. Appellate Authority (Delhi High Court, 2012)

Subject: Non-relative donations, affection and the prohibition on commercial transactions.

The decision is cited in subsequent transplantation litigation for the proposition that lawful donations may arise from genuine affection or attachment even where the donor and recipient are not close relatives. The legal system seeks to prevent commercial exploitation without unnecessarily obstructing genuine donations.

Indian Kanoon

+1

Relevance: Tissue procurement policies should not confuse a legitimate donation with a prohibited commercial transaction merely because the donor and recipient are unrelated. Whether the case applies directly depends on the material and the statutory framework governing it.

Case 4: Riegel v. Medtronic, Inc. (United States Supreme Court, 2008)

Citation: 552 U.S. 312 (2008).

Subject: Federal pre-emption of certain medical-device product-liability claims.

The Court held that federal pre-market approval requirements for the medical device at issue pre-empted certain state-law claims imposing requirements different from or additional to federal requirements.

Legal Information Institute

Relevance: An engineered tissue product classified as a medical device in a particular jurisdiction may be subject to specialized regulatory approval and product-liability rules. The case illustrates the interaction between product authorization and civil litigation.

Limitation: This is a United States decision concerning a medical device, not an Indian tissue-procurement case. Its holding does not automatically apply to tissue-engineered products or to Indian law.

Case 5: Indian Society of Organ Transplantation v. Union of India (Supreme Court of India, 2025)

Subject: Equality and access in organ donation.

The Supreme Court considered issues concerning uniformity, equality and access for donors and recipients under the Indian transplantation framework.

Sci API

Relevance: The judgment provides a contemporary context for considering whether regulatory processes are consistent, accessible and administered fairly. These concerns are also relevant to access to engineered tissue treatments, although any extension to such products requires analysis of the specific legal regime.

Case 6: Dr. Jyoti Bansal v. State of Rajasthan (Rajasthan High Court, 2024)

Subject: Alleged commercial organ-transplantation arrangements.

The Court declined to quash criminal proceedings at the investigation stage where allegations and material concerning paid donors, brokers and financial transactions required investigation under the applicable transplantation law.

IndiaCode

Relevance: Procurement organizations should preserve financial, sourcing and transaction records and investigate warning signs of unlawful biological-material acquisition.

Limitation: The decision concerned alleged kidney-transplantation dealings. It does not establish that every commercial transaction involving a tissue-engineered product is prohibited.

6. Civil and criminal liability for unlawful procurement

Liability depends on the conduct, the material involved, the applicable law and the evidence.

A company cannot avoid liability merely by outsourcing procurement to a supplier. Contracts can allocate responsibilities, but they do not necessarily eliminate statutory duties or liability for a party's own misconduct.

Conversely, an adverse clinical outcome does not automatically establish negligence. A claimant generally must establish the relevant legal elements, which may include breach of duty, defect, causation and legally recognized harm.

7. Recent Indian regulatory developments relevant to artificial tissues

India's regulation of advanced cell-based and tissue-engineered products is evolving. Two developments are particularly important.

A. Yash Charitable Trust v. Union of India (2026)

The Bombay High Court's judgment dated 30 January 2026 addresses the distinction between processed stem-cell-derived products and stem-cell therapies. The judgment discusses the New Drugs and Clinical Trials Rules, 2019, the Drugs and Cosmetics Act, 1940, and the regulatory status of different types of stem-cell interventions.

Indian Kanoon

The important analytical distinction is between a product made through substantial manipulation of cells or tissues and the use of cells that have not undergone such manipulation. The applicable regulatory pathway depends on the characteristics and intended use of the intervention; it should not be assumed that every procedure involving cells is legally identical.

B. Central licensing changes announced in July 2026

The Ministry of Health and Family Welfare announced amendments to the Drugs Rules, 1945, bringing specified cell- or stem-cell-derived products, gene-therapeutic products and xenografts within the Centrally License Approving Authority framework.

Press Information Bureau

+1

This is significant for tissue procurement because the procurement, processing and manufacture of biological starting materials may form part of a regulated product's development and licensing pathway.

For a tissue-engineered product, manufacturers should therefore verify the applicable current licensing provisions, product classification, clinical-trial requirements and manufacturing permissions before commencing clinical supply.

8. Practical example

Suppose a biotechnology company manufactures artificial skin using a patient's cells and a synthetic scaffold.

The legal analysis would proceed as follows:

Cell sourcing: Establish that the patient's cells were lawfully collected and that consent covers the intended processing and clinical use.

Manufacturing: Document the scaffold, cell-processing method, manufacturing controls and batch traceability.

Classification: Determine whether the resulting product falls within a regulated cell-derived product, medical-device or other applicable category.

Clinical use: Obtain the approvals required for the particular investigation or treatment.

Commercial supply: Verify the necessary manufacturing and marketing authorizations and distinguish lawful product charges from any prohibited transaction involving human tissue.

Liability: Establish procedures for adverse-event reporting, patient follow-up, complaints and product recalls.

If the same company instead obtains donated human skin from a tissue bank and processes it for grafting, the THOTA framework and the 2014 Rules may be directly relevant to procurement and tissue-bank operations. The precise classification must still be assessed against the facts and applicable law.

IndiaCode

+2

9. Major legal challenges and reforms

Several issues remain important for the development of a coherent artificial-tissue procurement framework.

Classification uncertainty: The boundaries between human tissue, engineered living constructs, biological products and synthetic substitutes can be difficult to determine.

Consent for secondary use: Original donation consent may not resolve every question involving future research, genetic modification or commercial development.

Ownership and commercialization: The respective rights of donors, research institutions, tissue banks and manufacturers require careful contractual and legal treatment.

Safety and long-term monitoring: Living constructs may behave differently from conventional inert medical materials and may require specialized follow-up.

Cross-border procurement: Importing biological starting materials can raise additional licensing, customs, biosafety, ethical and data-transfer questions.

Equitable access: High production costs and proprietary manufacturing methods may limit access to innovative tissue-replacement treatments.

Potential reforms include clearer classification criteria, harmonized tissue traceability standards, stronger donor-consent documentation, transparent pricing, risk-based authorization and consistent post-market surveillance.

10. Conclusion

Artificial Tissue Procurement Law is best understood as a developing field rather than a single statutory regime. Its central concern is ensuring that biological materials and engineered tissue products are sourced lawfully, manufactured safely, used with appropriate consent and supplied under the correct regulatory authorization.

In India, THOTA and the Transplantation of Human Organs and Tissues Rules, 2014 are central to the procurement of human tissues for transplantation. The Drugs and Cosmetics framework and applicable product-specific rules become particularly important for engineered cell-based and tissue-derived products. The exact legal route depends on the product's biological composition, processing, intended use and regulatory classification.

The transplantation cases discussed above establish useful principles concerning consent, authorization, prevention of exploitation and fair administration. They should not be cited as if they had conclusively decided ownership or procurement rights in laboratory-grown tissues.

For academic or legal research, the most important question is therefore: Is the material a donated human tissue, a substantially processed cell-derived product, a hybrid tissue-engineered construct, or a wholly synthetic substitute? Answering that question is the starting point for identifying the applicable law, regulatory authority, consent requirements and potential liability.

This explanation is educational and focuses on Indian law. For an actual procurement, research or commercialization arrangement, the applicable legislation, current notifications and product-specific regulatory classification should be verified before action is taken.